Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - PhaseBio Pharmaceuticals Inc | ex-321xphas10xq2021q1.htm |
| EX-31.2 - EX-31.2 - PhaseBio Pharmaceuticals Inc | ex312-phas10xq2021q1.htm |
| EX-31.1 - EX-31.1 - PhaseBio Pharmaceuticals Inc | ex311-phas10xq2021q1.htm |
| EX-10.2 - EX-10.2 - PhaseBio Pharmaceuticals Inc | ex102-phas10xq2021q1.htm |
| 10-Q - 10-Q - PhaseBio Pharmaceuticals Inc | phas-20210331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of PhaseBio Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| Date: May 13, 2021 | By: | /s/ John P. Sharp | |||||||||
| John P. Sharp Chief Financial Officer | |||||||||||